AGS Therapeutics, based in Paris and Genopole (www.genopole.fr), Evry, France, is a biotech company pioneering the use of microalgae extracellular vesicles (MEVs) as a universal delivery system for innovative biologics, vaccines and gene therapies. AGS has shown MEVs to be a safe, targeted and highly versatile delivery system for mRNA, siRNA, DNA oligos, plasmids, proteins, and peptides relevant to a broad range of human diseases.
AGS Therapeutics has two lead therapeutic candidates in development, both addressing multi-billion markets with significant unmet needs:
• AGS-1010 for wet age-related macular degeneration (wAMD), with a potential breakthrough in topical administration (eye drops) that could significantly improve patient comfort and compliance compared to current standard-of-care (injections into the eye).
• AGS-2010 for inflammatory bowel disease (IBD), offering a non-systemic oral treatment option.
AGS-M, the company’s CDMO subsidiary, produces the MEVs needed to support R&D from AGS and from companies partnering with AGS. AGS’ MEVs are derived from Chlorella, a two-billion-year-old single-cell algae, labelled by the FDA as GRAS for consumption as a food supplement. AGS’ MEVs are easy to manufacture in large quantities with processes that are both eco-friendly and easily scalable. Through strategic partnerships and a commitment to scientific excellence, the company aims to challAGS-M, a contract development and manufacturing organization, produces the MEVs needed to support preclinical and clinical development of MEV-based product pipelines from AGS Therapeutics, and from pharmaceutical and other companies partnering with AGS.
AGS’ MEVs are derived from Chlorella, a 2-billion-year-old single-cell algae used for decades as a food supplement. AGS’ MEVs are easy to manufacture in large quantities with simple cell culture media production techniques that are both eco-friendly and easily scalable. For more information visit www.ags-tx.com and www.ags-m.com.
